Brenntag has entered into a new strategic partnership with Evonik Rexim for the distribution of GMP-compliant amino acids in the European pharmaceutical and biopharmaceutical markets. The agreement covers most of Europe, including the DACH region, the United Kingdom, France, Benelux, Scandinavia, CEE, Israel, Turkey, and more (excluding Italy, Ukraine, the Middle East, and Africa).
Evonik Rexim is a leading supplier of high-quality amino acids and offers European shipping for a large portion of its production. The company combines market leadership in the areas of fermentation, bioconversion, and synthetic manufacturing. The partnership with Brenntag supports the strategy to expand its presence in key global markets and offers customers improved local service, technical support, and long-term supply reliability.
“Our collaboration with Evonik reflects Brenntag’s commitment to bringing high-quality pharmaceutical ingredients and solutions closer to our customers,” says Joakim Rehné, President of Brenntag Pharma EMEA. “Together, we are creating a stronger, more reliable supply network that accelerates innovation and ensures patients’ access to critical therapies,” Rehné continues.
“Our partnership with Brenntag significantly strengthens Evonik Rexim’s market reach,” says Thomas Hermann, Head of the Rexim product line at Evonik Health Care. “Brenntag’s strong regional presence, close customer relationships, and extensive experience in the life sciences sector make it an ideal partner. Together, we can offer our customers reliable access to high-quality GMP-compliant amino acids and support the rapidly growing pharmaceutical and biopharmaceutical markets.”
Source: chemanager-online.com
Samsung Biologics announced the launch of an all-cash public tender offer to acquire 100% of the fully diluted share capital of PolyPeptide Group, a leading global contract development and manufacturing organization (CDMO) specializing in peptide-based active pharmaceutical ingredients (APIs).
Aptar Pharma has launched a collaborative system-level framework designed to support the development of injectable drug delivery systems. The framework will enable pharmaceutical partners to access integrated data packages combining system-level testing and performance data for injectable therapies.
According to a global women’s health investment report from W Group, disclosed equity secured by companies in the space last year was up 41% compared to 2024. The report tracked more than 500 funding stories and around 164 disclosed rounds of equity across clinical and consumer categories.
